Lorlatinib - PF-06463922
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03127618 |
|
Expanded Access Status :
Approved for marketing
First Posted : April 25, 2017
Last Update Posted : May 15, 2020
|
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
| Tracking Information | |
|---|---|
| First Submitted Date | April 20, 2017 |
| First Posted Date | April 25, 2017 |
| Last Update Posted Date | May 15, 2020 |
| Descriptive Information | |
| Brief Title | Lorlatinib - PF-06463922 |
| Official Title | Not Provided |
| Brief Summary | Lorlatinib expanded access program |
| Detailed Description | Not Provided |
| Study Type | Expanded Access |
| Expanded Access Type | Individual Patients |
| Condition | Not Provided |
| Intervention | Drug: Lorlatinib |
| Publications * | Not Provided |
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
| Recruitment Information | |
| Expanded Access Status | Approved for marketing |
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: - |
| Sex/Gender | Not Provided |
| Ages | 18 Years and older (Adult, Older Adult) |
| Contacts | Contact information is only displayed when the study is recruiting subjects |
| Listed Location Countries | Not Provided |
| Removed Location Countries | |
| Administrative Information | |
| NCT Number | NCT03127618 |
| Other Study ID Numbers | B746 |
| Current Responsible Party | Pfizer |
| Original Responsible Party | Same as current |
| Current Study Sponsor | Pfizer |
| Original Study Sponsor | Same as current |
| Collaborators | Not Provided |
| Investigators | Not Provided |
| PRS Account | Pfizer |
| Verification Date | May 2020 |